Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

What this study is about

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.

Who can join (things the study team will check)

✅ You may be able to join if…

• Refractory hypercholesterolemia
• Refractory hypertriglyceridemia

🚫 You may not be able to join if…

• Active or history of chronic liver disease
• Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
• Clinically significant or abnormal laboratory values as defined by the protocol

Where this trial is running

• Clinical Study Center, Clearwater, Florida, United States
• Clinical Study Center, Miami Lakes, Florida, United States
• Clinical Study Center, Port Orange, Florida, United States
• Clinical Study Center, New York, New York, United States
• Clinical Study Center, Adelaide, Australia
• Clinical Study Center, Melbourne, Australia
• Clinical Study Center, Chicoutimi, Canada
• Clinical Study Center, Montreal, Canada
• Clinical Study Center, Toronto, Canada
• Clinical Study Center, Amsterdam, Netherlands
• Clinical Study Center, Cape Town, South Africa
• Clinical Study Center, Johannesburg, South Africa

+ 4 more sites.

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06451770.